摘要:
The present invention relates to novel N -cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N -oxides thereof, their uses as therapeutic agents and the methods of their making.
摘要:
The present invention relates to novel alkanoyl-substituted heterocyclic derivatives which are cysteine protease inhibitors; the pharmaceutically acceptable salts and N-oxides thereof; their uses as therapeutic agents and the methods of their making; according to Formal (I) in which: A comprises a heteromonocyclic ring containing 5 to 6 ring member atoms or a fused heteropolycyclic ring system containing 8 to 14 ring member atoms, wherein each ring contains 5 to 7 ring member atoms, X 1 is a ring member carbon atom and each ring member other than X 1 is a carbon atom or a heteroatom, with the proviso that (i) at least one ring member atom is a heteroatom and (ii) when A is a heteromonocyclic radical containing 5 ring member atoms, no more than two of the ring member atoms comprising A are heteroatoms; n is 0, 1, 2 or 3; X 1 is =C- or -CH-; X 2 is a bond or a divalent group of Formula (a) or (b); R 1 - R 8 = as in the application.
摘要翻译:本发明涉及新型烷酰基取代的杂环衍生物,它们是半胱氨酸蛋白酶抑制剂; 其药学上可接受的盐和N-氧化物; 它们作为治疗剂的用途及其制备方法; 根据Formal(I),其中:A包含含有5至6个环成员原子的杂单环或含有8至14个环成员原子的稠合杂多环系,其中每个环含有5至7个环成员原子,X 1, 是环成员碳原子,除X 1之外的每个环成员是碳原子或杂原子,条件是(i)至少一个环原子是杂原子,和(ii)当A是异单环基团时 含有5个环成员原子,不超过两个包含A的环成员原子是杂原子; n为0,1,2或3; X 1 = C或-CH-; X 2为式(a)或(b)的键或二价基团; R 1 -R 8 =如申请中所述。
摘要:
The present invention relates to novel N -cyanomethyl amides which are cysteine protease inhibitors, the pharmaceutically acceptable salts and N -oxides thereof, their uses as therapeutic agents and the methods of their making.